Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Phase 2 Unknown 120 enrolled Fudan University

RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

Timeline

Start: 2020-06-08
Primary completion: 2021-12-31
Completion: 2022-12-31

Publications

Zhao X, Wu X, Wang H, Yu H, Sun S, Hu Z, Lin Y, Zhang Y, Yu B, Wu Z, Xiong K, Liu C, Wang S, Bao H, Ou Q, Wang J. Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers. Transl Lung Cancer Res. 2025 Oct 31;14(10):4315-4330. doi: 10.21037/tlcr-2025-545. Epub 2025 Oct 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	—
Comparator	Gefitinib	Small molecule	250 mg	Oral

Indications

No indication recorded.